<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177137</url>
  </required_header>
  <id_info>
    <org_study_id>U01DC007422</org_study_id>
    <secondary_id>U01DC007422</secondary_id>
    <nct_id>NCT01177137</nct_id>
  </id_info>
  <brief_title>Tinnitus Retraining Therapy Trial</brief_title>
  <acronym>TRTT</acronym>
  <official_title>Tinnitus Retraining Therapy Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama, Tuscaloosa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>David Grant U.S. Air Force Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wilford Hall Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Naval Medical Center, San Diego</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Naval Medical Center, Portsmouth</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naval Hospital Camp Pendleton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the Tinnitus Retraining Therapy Trial (TRTT) is to assess the efficacy
      of tinnitus retraining therapy (TRT) as a treatment for severe debilitating tinnitus. TRT is
      a non-medical intervention that uses directive counseling (DC) and sound therapy (ST)to
      habituate the patient's associated negative emotional reactions to tinnitus, its perception,
      and ultimately, its impact on the patient's life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Tinnitus Retraining Therapy Trial (TRTT), funded by the National Institute of Deafness
      and Other Communication Disorders, is a multi-center randomized clinical trial testing the
      efficacy of tinnitus retraining therapy (TRT) versus standard-of-care (SC) treatment in
      individuals who have self-perceived intolerable tinnitus. TRT is a non-medical intervention
      that uses directive counseling (DC) and low-level sound therapy (ST) achieved through sound
      generators (SGs) to habituate the patient's associated negative emotional reactions
      (annoyance) to tinnitus, its perception (awareness) and, ultimately, its impact on the
      participant's life. Study participants will include active and retired military personnel of
      the U. S. Armed Forces and their dependents who suffer from severe tinnitus. The study will
      be conducted at flagship Air Force, and Navy Medical Centers.

      This trial will evaluate the efficacy of TRT and its components (DC and ST) versus the
      standard of care (SC) as administered in the military by comparing the efficacy of:

        -  (1) TRT (DC and ST achieved using conventional sound generators) versus SC;

        -  (2) TRT versus partial TRT (DC and placebo sound generators) to evaluate the separate
           effect of sound therapy, under the assumption that placebo noise generator will not
           provide any meaningful sound therapy beyond that found in SC;

        -  (3) partial TRT versus SC to evaluate the separate effect of DC.

      Eligibility will be determined at the Baseline Eligibility Visit, which will consist of a
      medical and tinnitus history, physical examination, and baseline
      audiological/tinnitus/hyperacusis evaluation. Study participants will also complete a series
      of quality of life and psychological profile tests. Study Audiologists will administer the
      randomly assigned treatment. Follow-up visits at Clinical Centers will take place at 3, 6,
      12, and 18 months and include completion of tinnitus outcome questionnaires at all visits.
      Psychometric testing and audiological/tinnitus/hyperacusis evaluation will take place at the
      6, 12, and 18 month visits. Evaluation of audiometric pure tone and loudness discomfort level
      also will take place at treatment visits.

      The primary outcome to be measured in the TRTT will be change in scores on the Tinnitus
      Questionnaire (TQ) longitudinally assessed between baseline and follow-up (i.e., at 3, 6, 12
      and 18 months following treatment). Secondary outcomes include changes in the sub-scales of
      the TQ, change in scores from the Tinnitus Handicap Inventory (THI), Tinnitus Functional
      Index (TFI), Hearing Handicap Inventory (HHI), and TRT visual analogue scales, and change in
      the Digit Symbol Substitution Test (DSST). Psychometric secondary outcomes also include
      change in psychoacoustic variables related to the tinnitus sensation, including tinnitus
      pitch and loudness match, and loudness discomfort level.

      The TRTT is designed to have sufficient power to detect a minimal clinically important
      difference in the Tinnitus Questionnaire (TQ) i.e., a 10 point difference between TRT and SC
      groups on change in TQ global scores longitudinally assessed over the course of follow-up and
      a 7-point difference on TQ score by TRT components, DC and ST.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2011</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in score on the Tinnitus Questionnaire (TQ)</measure>
    <time_frame>Baseline to 3, 6, 12, and 18 months follow-up</time_frame>
    <description>Initial TQ administration will determine eligibility (score greater than or equal to 40) for the TRTT. The primary outcome is a repeated measures analysis of change in TQ score from baseline to follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in TQ sub-scale scores</measure>
    <time_frame>Baseline to 3, 6, 12, and 18 months follow-up</time_frame>
    <description>Repeated measures analysis of change in sub-scale scores from baseline to follow-up. Sub-scales include the following: psychological distress, intrusiveness, hearing difficulties, sleep disturbances, and somatic complaints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tinnitus Handicap Inventory (THI) score</measure>
    <time_frame>Baseline to 3, 6, 12, and 18 months follow-up</time_frame>
    <description>Repeated measures analysis of change in overall and sub-scale scores from baseline to follow-up. Subscales include the following: functional, emotional; and catastrophic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tinnitus Functional Index (TFI) score</measure>
    <time_frame>Baseline to 3, 6, 12, and 18 months follow-up</time_frame>
    <description>Repeated measures of change from baseline to follow-up in health related quality of life domains affected by tinnitus. Domains include intrusiveness, reduced sense of control, cognitive interference, sleep disturbance, auditory difficulties (related to tinnitus), relaxation interference, reduced quality of life, and emotional distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TRT Interview Visual Analogue scales</measure>
    <time_frame>Baseline to 3, 6, 12, and 18 months follow-up</time_frame>
    <description>Repeated measures analysis of change in score from baseline to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Baseline to 6 and 18 months follow-up</time_frame>
    <description>Repeated measures analysis of change in score from baseline to follow-up. This test assesses cognitive function related to ability to focus attention to a task and recall and is an indirect measure of ability to ignore the tinnitus signal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychoacoustic variables</measure>
    <time_frame>Baseline to 6 and 18 months follow-up</time_frame>
    <description>Repeated measures analysis of change from baseline to follow-up in tinnitus pitch and loudness match and loudness discomfort level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hearing Handicap Inventory (HHI)</measure>
    <time_frame>Before randomized treatment assignment is requested to 6 and 18 months follow-up</time_frame>
    <description>The HHI is a measure of the impact of hearing difficulties on the quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Subjective Tinnitus</condition>
  <arm_group>
    <arm_group_label>TRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRT includes treatment with a conventional sound generator (SG) and directive counseling (DC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Partial TRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Partial TRT includes treatment with a placebo sound generator (placebo SG) and directive counseling (DC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The standard of care arm includes care as typically delivered in US military medical centers</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional sound generator (SG)</intervention_name>
    <description>Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)</description>
    <arm_group_label>TRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo sound generator (placebo SG)</intervention_name>
    <description>Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.</description>
    <arm_group_label>Partial TRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of Care (SC)</intervention_name>
    <description>The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.</description>
    <arm_group_label>Standard of Care (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Directive Counseling (DC)</intervention_name>
    <description>Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.</description>
    <arm_group_label>TRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Directive Counseling (DC)</intervention_name>
    <description>Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.</description>
    <arm_group_label>Partial TRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or above

          -  Subjective severe tinnitus, defined as a score on the Tinnitus Questionnaire (TQ)
             greater than or equal to 40

          -  Eligible for care at a Department of Defense Clinical Center

          -  Speaks English well enough to complete a series of questionnaires and benefit from
             counseling

        Exclusion Criteria:

          -  Involvement in pending tinnitus-related financial claims or litigation except that
             associated with usual Veterans' Administration retirement claims

          -  Tinnitus of less than 12 months duration

          -  Treatment for tinnitus within previous 12 months

          -  Routine unavoidable exposure to hazardous noise

          -  Use of a cancer chemotherapeutic drug within previous 12 months

          -  Treatment for head or neck injury within previous 24 months

          -  Treatment for an emotional, psychological, or psychiatric condition within previous 12
             months resulting in inability to participate in the trial or complete all followup
             visits, as assessed by best clinical judgment

          -  Requirement for use of an ototoxic drug

          -  Hearing impairment, defined by audiometric thresholds &gt; 30 dB HL at and below 2,000 Hz
             and &gt; 40 dB HL at 4,000 and 8,000 Hz

          -  Required use of hearing aids

          -  Fluctuating hearing loss at a level that would interfere with the reliability of study
             results

          -  One or more prominent spontaneous otoacoustic emissions, defined as the presence of a
             spontaneous otoacoustic emission spike that is 3 or more times larger than the
             measured variation in amplitude across the remaining frequency range and/or if the
             emission corresponds in pitch to the tinnitus pitch

          -  Pulsatile somatosounds suggesting presence of abnormal vasculature or high blood
             pressure contributing to the tinnitus

          -  Feigning tinnitus or hearing loss

          -  Evidence by audiological testing of a treatable etiology of the tinnitus, such as
             conductive hearing impairment as shown by pure-tone thresholds, abnormal acoustic
             immittance, abnormal stapedial reflex test, or abnormal auditory brainstem response

          -  Predisposing disease with tinnitus symptoms amenable to medical or surgical
             intervention, including but not limited to; chronic otitis media, otosclerosis,
             vestibular disorder or dizziness, Eustachian tube, middle ear, or inner ear disease,
             Lyme disease or ear autoimmune disease, malocclusion or temporomandibular joint
             disease, uncontrolled allergies, aberrant ear, head, or neck blood vasculature or
             glomus tumor, neurological condition such as multiple sclerosis or ear-related
             demyelinating disease, perilymphatic fistula, or facial weakness or paralysis

          -  Meniere's disease

          -  Uncontrolled diabetes, defined as blood glucose consistently â‰¥ 200 mg/dl or an HBA1c
             above 8%

          -  Evidence from any laboratory study that suggests an etiology for the tinnitus that is
             treatable, including, but not limited to, abnormal thyroid stimulating hormone (TSH)
             or thyroid hormone (T3 or T4) levels, positive fluorescent treponemal antibody (FTA)
             test, or positive Lyme titer

          -  Evidence of a tumor contributing to the tinnitus, including an acoustic neuroma (or
             vestibular schwannoma), cerebellopontine angle tumor, skull base tumor, or any other
             type of tumor that the examining physician believes is responsible for the tinnitus

          -  Diagnosis of traumatic head or brain injury requiring treatment

          -  Diagnosis of an emotional, psychological, or psychiatric condition requiring treatment
             and resulting in inability to participate in the trial or complete all followup
             visits, as assessed by best clinical judgment

          -  Inability or unwillingness of patient to comply with study requirements

          -  Unwillingness of Clinical Center Director to randomize the patient to treatment due to
             the presence of any condition, physical, mental or social, which is likely to affect
             the patient returning for follow-up visits on schedule or which is likely to impair
             his or her performance on the functional tests

          -  Inability or unwillingness of patient to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Craig Formby, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Alabama, Tuscaloosa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberta W Scherer, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Hospital Camp Pendleton</name>
      <address>
        <city>Camp Pendleton</city>
        <state>California</state>
        <zip>92055-5191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Grant Medical Center</name>
      <address>
        <city>Travis AFB</city>
        <state>California</state>
        <zip>94535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilford Hall Medical Center</name>
      <address>
        <city>Lackland AFB</city>
        <state>Texas</state>
        <zip>78236-5300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Naval Medical Center</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23705-2103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Scherer RW, Formby C, Gold S, Erdman S, Rodhe C, Carlson M, Shade D, Tucker M, Sensinger LM, Hughes G, Conley GS, Downey N, Eades C, Jylkka M, Haber-Perez A, Harper C, Russell SK, Sierra-Irizarry B, Sullivan M; Tinnitus Retraining Therapy Trial Research Group. The Tinnitus Retraining Therapy Trial (TRTT): study protocol for a randomized controlled trial. Trials. 2014 Oct 15;15:396. doi: 10.1186/1745-6215-15-396.</citation>
    <PMID>25319676</PMID>
  </reference>
  <reference>
    <citation>Formby C, Scherer R; TRTT Study Group. Rationale for the tinnitus retraining therapy trial. Noise Health. 2013 Mar-Apr;15(63):134-42. doi: 10.4103/1463-1741.110299.</citation>
    <PMID>23571304</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Roberta Scherer</investigator_full_name>
    <investigator_title>Director, Data Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>tinnitus</keyword>
  <keyword>tinnitus retraining therapy</keyword>
  <keyword>standard of care</keyword>
  <keyword>directive counseling</keyword>
  <keyword>sound therapy</keyword>
  <keyword>tinnitus questionnaire</keyword>
  <keyword>tinnitus handicap inventory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Requests for limited datasets may be made to the TRTT Data Coordinating Center</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

